StemCells (STEM) Misses Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
StemCells, Inc. Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Business Update
March 16, 2015 4:05 PM EDTNEWARK, Calif., March 16, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq: STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics for diseases of the central nervous system, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2014.
"We achieved three significant clinical translation milestones in 2014: the completion of enrollment in two Phase I/II studies and initiation of the first of two planned, multicenter Phase II proof of concept studies using our proprietary human neural stem cell platform," said Martin McGlynn, President... More
